Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01247272 · ClinicalTrials.gov registry record · Phase 1
90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01247272: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT01247272 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01247272, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study compared the relative bioavailability (rate and extent of absorption) of 90 mg Fluoxetine Hydrochloride Capsules by Teva Pharmaceuticals, USA with that of 90 mg PROZAC WEEKLY® Capsules by Eli Lilly and Company following a single oral dose (1 x 90 mg) in healthy adult volunteers under fasting conditions.
Interventions
- DRUG Fluoxetine Hydrochloride
- DRUG PROZAC WEEKLY®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2001-05 |
| Est. Completion | 2001-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01247272
The ClinicalTrials.gov registry entry for NCT01247272 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluoxetine Hydrochloride is the first listed.
NCT01247272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01247272 about?
NCT01247272 is a clinical study titled "90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions". This study compared the relative bioavailability (rate and extent of absorption) of 90 mg Fluoxetine Hydrochloride Capsules by Teva Pharmaceuticals, USA with that of 90 mg PROZAC WEEKLY® Capsules by Eli Lilly and Company following a single oral dose (1 x 90 mg) in healthy adult volunteers under fast...
What is the current status of trial NCT01247272?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2001-05. Estimated completion is 2001-07.
What interventions are being tested in trial NCT01247272?
The interventions under investigation include: Fluoxetine Hydrochloride (DRUG), PROZAC WEEKLY® (DRUG).
Who is sponsoring clinical trial NCT01247272?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.